Preterm LaborNCT07696858
Short-Term Tocolysis in Preterm Labor
An observational study of Preterm Labor, run by Sohag University.
Trial summary
The aim of this study is to identify independent prognostic factors associated with the success of short-term tocolysis, defined as delivery delayed by at least 48 hours, in women with singleton preterm labor Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Preterm Labor
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 Aug 2026to 1 Jul 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Study population: All participants will receive short-term tocolytic therapy according to the unit protocol. * The choice of tocolytic agent (., Magnesium sulphate ) will be determined by the treating physician. * Tocolysis will be administered for a maximum duration of 48-72 hours. * Antenatal corticosteroids (Betamethasone amp 12mg once daily for 2days) will be administered to eligible participants to enhance fetal lung maturity. * Failure documented when there is efficient uterine contractions more 4/10mins each one lasts more than 40 seconds, and there was progressive cervical dilatation more 3cm
Who may be able to join
- Age from 18 to 45 years old.
- Singleton Pregnancy
- Gestational age between 24 and 34 weeks, confirmed by last menstrual period and/or first-trimester ultrasound.
- Diagnosis of preterm labor, defined as Regular uterine contractions (≥4 in 20 minutes recorded in CTG) with a documented change in cervical dilation (e.g., from<1 cm to ≥2 cm) or, in nulliparous women, a dilation of ≥2 cm
- Intact membranes at the time of presentation.
Who cannot join
- Established preterm labor (efficient uterine contractions 4/10mins each one lasts more than 40 Seconds recorded in CTG, with cervical changes (dilatation>4cm, effacement>80%)).
- Evidence of chorioamnionitis or intrauterine infection.
- Preterm premature rupture of membranes (PPROM).
- Maternal medical disorders contraindicating tocolysis, such as severe preeclampsia, significant cardiac disease, or uncontrolled diabetes mellitus.
- Contraindications to continuation of pregnancy, including placental abruption or placenta previa with bleeding.
- Vaginal bleeding of unknown origin" as a specific exclusion criterion, as it may indicate abruption or other pathologies.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Mohamed Hussein Abdelatif Teleb Hussein Abdelatif Teleb, resident contact
About this study
Official title: Prognostic Factors Affecting the Success of Short-Term Tocolysis in Preterm Labor
The aim of this study is to identify independent prognostic factors associated with the success of short-term tocolysis, defined as delivery delayed by at least 48 hours, in women with singleton preterm labor
Read the detailed description
All participants will receive short-term tocolytic therapy according to the unit protocol.
- The choice of tocolytic agent (., Magnesium sulphate ) will be determined by the treating physician.
- Tocolysis will be administered for a maximum duration of 48-72 hours.
- Antenatal corticosteroids (Betamethasone amp 12mg once daily for 2days) will be administered to eligible participants to enhance fetal lung maturity.
- Failure documented when there is efficient uterine contractions more 4/10mins each one lasts more than 40 seconds, and there was progressive cervical dilatation more 3cm
- Conditions
- Preterm Labor
- Keywords
- tocolysis, preterm labor
- Medical subject headings
- Obstetric Labor, Premature
What is being measured
The primary outcome is the main question the study is designed to answer.
Successful short-term tocolysis, defined as postponement of delivery for at least 48 hours after initiation of tocolytic therapy
Measured: 48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2026
- Study start1 Aug 2026 (estimated)
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Preterm LaborStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Taleb Hussein Abdellattif, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07696858
- Sponsor's protocol ID
- Soh-Med-26-6-26MS
- Status last verified
- Jul 2026
- First submitted
- 6 Jul 2026
- Last updated
- 10 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Factors Affecting the Success of Short-Term Tocolysis in Preterm Labor
- ClinicalTrials.gov ID
- NCT07696858
- Acronym / sponsor ID
- Soh-Med-26-6-26MS
- Conditions
- Preterm Labor
- Keywords
- tocolysis, preterm labor
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Aug 2026 (estimated)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Jul 2027 (estimated)
- First posted
- 10 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to identify independent prognostic factors associated with the success of short-term tocolysis, defined as delivery delayed by at least 48 hours, in women with singleton preterm labor
Detailed description
All participants will receive short-term tocolytic therapy according to the unit protocol.
- The choice of tocolytic agent (., Magnesium sulphate ) will be determined by the treating physician.
- Tocolysis will be administered for a maximum duration of 48-72 hours.
- Antenatal corticosteroids (Betamethasone amp 12mg once daily for 2days) will be administered to eligible participants to enhance fetal lung maturity.
- Failure documented when there is efficient uterine contractions more 4/10mins each one lasts more than 40 seconds, and there was progressive cervical dilatation more 3cm
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- All participants will receive short-term tocolytic therapy according to the unit protocol. * The choice of tocolytic agent (., Magnesium sulphate ) will be determined by the treating physician. * Tocolysis will be administered for a maximum duration of 48-72 hours. * Antenatal corticosteroids (Betamethasone amp 12mg once daily for 2days) will be administered to eligible participants to enhance fetal lung maturity. * Failure documented when there is efficient uterine contractions more 4/10mins each one lasts more than 40 seconds, and there was progressive cervical dilatation more 3cm
Key inclusion criteria (5 listed)
- Age from 18 to 45 years old.
- Singleton Pregnancy
- Gestational age between 24 and 34 weeks, confirmed by last menstrual period and/or first-trimester ultrasound.
- Diagnosis of preterm labor, defined as Regular uterine contractions (≥4 in 20 minutes recorded in CTG) with a documented change in cervical dilation (e.g., from<1 cm to ≥2 cm) or, in nulliparous women, a dilation of ≥2 cm
- Intact membranes at the time of presentation.
Key exclusion criteria (6 listed)
- Established preterm labor (efficient uterine contractions 4/10mins each one lasts more than 40 Seconds recorded in CTG, with cervical changes (dilatation>4cm, effacement>80%)).
- Evidence of chorioamnionitis or intrauterine infection.
- Preterm premature rupture of membranes (PPROM).
- Maternal medical disorders contraindicating tocolysis, such as severe preeclampsia, significant cardiac disease, or uncontrolled diabetes mellitus.
- Contraindications to continuation of pregnancy, including placental abruption or placenta previa with bleeding.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Successful short-term tocolysis, defined as postponement of delivery for at least 48 hours after initiation of tocolytic therapy
Time frame: 48 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Preterm Labor
RecruitingPhase 3
Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates
Sepsis, PROM, Preterm (Pregnancy)
Recruiting
The Effect of Breast Milk, 10% and 20% Dextrose on Pain and Physiological Variables During Heel Puncture in Infants
Newborn Care, Pain Management
Not yet recruiting
The Hemodynamic Impact of High-frequency Oscillatory Ventilation and Periodic Sighs in Preterm Infants
Preterm, Respiratory Distress Syndrome in Premature Infant
Active, not recruiting
Prone Positioning During Delayed Cord Clamping
Delayed Cord Clamping
Not yet recruiting
Strap To Reduce Apnea in Preterm Infants: A Randomized Crossover Trial
Apnea of Prematurity, Intermittent Hypoxemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mohamed Hussein Abdelatif Teleb Hussein Abdelatif Teleb, resident contact
Questions about this trial
What is this clinical trial studying?
An observational study of Preterm Labor, run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohamed Hussein Abdelatif Teleb Hussein Abdelatif Teleb, resident (01022475295, mohamedhussein199819@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Successful short-term tocolysis, defined as postponement of delivery for at least 48 hours after initiation of tocolytic therapy (time frame: 48 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2026.